ICH Harmonised Tripartite Guideline

Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use

Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on November 8, 2000, this guideline is recommended for adoption to the three regulatory parties to ICH.

(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002)

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

ICH Harmonised Tripartite Guideline

Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on November 8, 2000, this guideline is recommended for adoption to the three regulatory parties to ICH

(Numbering and Section Headers have been edited for consistency and use in e-CTD as agreed at the Washington DC Meeting, September 11-12, 2002)

OBJECTIVE OF THE GUIDELINE

This guideline presents the agreed upon common format for the preparation of a well-structured Common Technical Document for applications that will be submitted to regulatory authorities. A common format for the technical documentation will significantly reduce the time and resources needed to compile applications for registration of human pharmaceuticals and will ease the preparation of electronic submissions. Regulatory reviews and communication with the applicant will be facilitated by a standard document of common elements. In addition, exchange of regulatory information between Regulatory Authorities will be simplified.

BACKGROUND

Through the ICH process, considerable harmonisation has been achieved among the three regions in the technical requirements for the registration of pharmaceuticals for human use. However, until now, there has been no harmonisation of the organisation of the registration documents. Each region has its own requirements for the organisation of the technical reports in the submission and for the preparation of the summaries and tables. In Japan, the applicants must prepare the GAIYO, which organises and presents a summary of the technical information. In Europe, Expert Reports and tabulated summaries are required, and written summaries are recommended. The U.S. FDA has guidance regarding the format and content of the New Drug Application. To avoid the need to generate and compile different registration dossiers, this guideline describes a format for the Common Technical Document that will be acceptable in all three regions.

SCOPE OF THE GUIDELINE

This guideline primarily addresses the organisation of the information to be presented in registration applications for new pharmaceuticals (including biotechnology-derived products).

This guideline is not intended to indicate what studies are required. It merely indicates an appropriate format for the data that have been acquired. Applicants should not modify the overall organisation of the Common Technical Document as outlined in the guideline. However, in the Nonclinical and Clinical Summaries, applicants can modify individual formats if needed to provide the best possible presentation of the technical information, in order to facilitate the understanding and evaluation of the results.
GENERAL PRINCIPLES
Throughout the Common Technical Document, the display of information should be unambiguous and transparent, in order to facilitate the review of the basic data and to help a reviewer become quickly oriented to the application contents. Text and tables should be prepared using margins that allow the document to be printed on both A4 paper (E.U. and Japan) and 8.5 x 11” paper (U.S.). The left-hand margin should be sufficiently large that information is not obscured by the method of binding. Font sizes for text and tables should be of a style and size that are large enough to be easily legible, even after photocopying. Times New Roman, 12-point font, is recommended for narrative text. Every page should be numbered, according to the granularity document. Acronyms and abbreviations should be defined the first time they are used in each module. References should be cited in accordance with the current edition of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, International Committee of Medical Journal Editors (ICMJE) 1.

ORGANISATION OF THE COMMON TECHNICAL DOCUMENT
The Common Technical Document is organized into five modules. Module 1 is region specific. Modules 2, 3, 4, and 5 are intended to be common for all regions. Conformance with this guideline should ensure that these four modules are provided in a format acceptable to the regulatory authorities.

Module 1. Administrative Information and Prescribing Information
This module should contain documents specific to each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities.

Module 2. Common Technical Document Summaries
Module 2 should begin with a general introduction to the pharmaceutical, including its pharmacologic class, mode of action, and proposed clinical use. In general, the Introduction should not exceed one page.
Module 2 should contain 7 sections in the following order:
• CTD Table of Contents
• CTD Introduction
• Quality Overall Summary
• Nonclinical Overview
• Clinical Overview
• Nonclinical Written and Tabulated Summaries
• Clinical Summary
The organisation of these summaries is described in Guidelines for M4Q, M4S, and M4E.

1 The first edition of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals was conceived by the Vancouver Group and was published in 1979.
Module 3. Quality
Information on Quality should be presented in the structured format described in Guideline M4Q.

Module 4. Nonclinical Study Reports
The nonclinical study reports should be presented in the order described in Guideline M4S.

Module 5. Clinical Study Reports
The human study reports and related information should be presented in the order described in Guideline M4E.

The overall organisation of the Common Technical Document is presented on the following pages.
ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Module 1: Administrative Information and Prescribing Information
  1.1 Table of Contents of the Submission Including Module 1
  1.2 Documents Specific to Each Region (for example, application forms, prescribing information)

Module 2: Common Technical Document Summaries
  2.1 Common Technical Document Table of Contents (Modules 2-5)
  2.2 CTD Introduction
  2.3 Quality Overall Summary
  2.4 Nonclinical Overview
  2.5 Clinical Overview
  2.6 Nonclinical Written and Tabulated Summaries
     Pharmacology
     Pharmacokinetics
     Toxicology
  2.7 Clinical Summary
     Biopharmaceutic Studies and Associated Analytical Methods
     Clinical Pharmacology Studies
     Clinical Efficacy
     Clinical Safety
     Literature References
     Synopses of Individual Studies

Module 3: Quality
  3.1 Table of Contents of Module 3
  3.2 Body of Data
  3.3 Literature References

Module 4: Nonclinical Study Reports
  4.1 Table of Contents of Module 4
  4.2 Study Reports
  4.3 Literature References

Module 5: Clinical Study Reports
  5.1 Table of Contents of Module 5
  5.2 Tabular Listing of All Clinical Studies
  5.3 Clinical Study Reports
  5.4 Literature References
ANNEX: Granularity Document

The CTD specifies many section headings and numbers. Could guidance be provided for all modules on headings in relation to document location and the section headings within those documents?

As a consequence of this definition could guidance be given on how documents should be paginated and on what the module Table of Contents should therefore include?

Definition of a Document
In deciding whether one or more documents or files are appropriate, it should be considered that once a particular approach has been adopted, the same approach should be used throughout the life of the dossier.

Documents in either the paper or electronic dossier are defined as follows:

Module 2
The following separate documents should be provided:

2.2 Introduction
2.3 Quality Overall Summary Introduction
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6.1 Introduction
2.6.2 Pharmacology Written Summary
2.6.3 Pharmacology Tabulated Summary
2.6.4 Pharmacokinetics Written Summary
2.6.5 Pharmacokinetics Tabulated Summary
2.6.6 Toxicology Written Summary
2.6.7 Toxicology Tabulated Summary
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.2 Summary of Clinical Pharmacology Studies
2.7.3 Summary of Clinical Efficacy (a separate document for each indication)
2.7.4 Summary of Clinical Safety
2.7.5 Literature References
2.7.6 Synopses of Individual Studies

For the following sections of the Quality Overall Summary, the applicant can either submit one document with multiple subheadings and subsection numbering, as defined in the M4Q guidance:

2.3.S Drug Substance
2.3.P Drug Product
2.3.A Appendices
or submit one document for each of the defined subheadings and subsections, as follows: e.g.

2.3.S.1 General Information
2.3.S.2 Manufacture
2.3.S.3 Characterization
2.3.S.4 Control of Drug Substance
2.3.S.5 Reference Standards or Materials
2.3.S.6 Container Closure System
2.3.S.7 Stability

2.3.P.1 Description and Composition of the Drug Product
2.3.P.2 Pharmaceutical Development
2.3.P.3 Manufacture
2.3.P.4 Control of Excipients
2.3.P.5 Control of Drug Product
2.3.P.6 Reference Standards or Materials
2.3.P.7 Container Closure System
2.3.P.8 Stability

2.3.A.1 Facilities and Equipment
2.3.A.2 Adventitious Agents Safety Evaluation
2.3.A.3 Excipients

Similarly, the applicant can submit one document or multiple documents i.e. one document for each subsection, as defined according to the appropriate regional guidance(s), under 2.3.R Regional Information.

Module 3
A separate document should be provided for each of the following sections:

3.2.S.1.1 Nomenclature
3.2.S.1.2 Structure
3.2.S.1.3 General Properties
3.2.S.2.1 Manufacturer(s)
3.2.S.2.2 Description of Manufacturing Process and Process Controls
3.2.S.3.1 Elucidation of Structure and Other Characteristics
3.2.S.3.2 Impurities
3.2.S.4.1 Specification
3.2.S.4.4 Batch Analyses
3.2.S.4.5 Justification of Specification
3.2.S.6 Container Closure System
3.2.S.7.1 Stability Summary and Conclusions
3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment
3.2.S.7.3 Stability Data

3.2.P.1 Description and Composition of the Drug Product
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.4.5 Excipients of Human or Animal Origin
3.2.P.4.6 Novel Excipients
3.2.P.5.1 Specification(s)
3.2.P.5.4 Batch Analyses
3.2.P.5.5 Characterisation of Impurities
3.2.P.5.6 Justification of Specification(s)
3.2.P.7 Container Closure System
3.2.P.8.1 Stability Summary and Conclusion
3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment
3.2.P.8.3 Stability Data

For the following sections, the applicant can submit, for each section, one document or multiple documents, e.g. one for each material, step, validation study, study report, reference standard or material, facility, or excipient, as the case may be:

3.2.S.2.3 Control of Materials
3.2.S.2.4 Controls of Critical Steps and Intermediates
3.2.S.2.5 Process Validation and/or Evaluation
3.2.S.2.6 Manufacturing Process Development
3.2.S.4.2 Analytical Procedures
3.2.S.4.3 Validation of Analytical Procedures
3.2.S.5 Reference Standards or Materials

3.2.P.2 Pharmaceutical Development
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4.1 Specifications
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
3.2.P.5.2 Analytical Procedures
3.2.P.5.3 Validation of Analytical Procedures
3.2.P.6 Reference Standards or Materials

3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients

For the Pharmaceutical Development section, one document can be provided covering all subsections but an applicant can also decide to submit several documents, in which case one document should be provided for each subsection, namely: 3.2.P.2.1, 3.2.P.2.2, 3.2.P.2.3, 3.2.P.2.4, 3.2.P.2.5, and 3.2.P.2.6.

The applicant can submit one document or multiple documents, i.e. one document for each subsection, as defined according to the appropriate regional guideline(s), under 3.2.R Regional Information.

Module 4
Typically a single document should be provided for each study report included in Module 4. However, where the study report is large, e.g., a carcinogenicity study, the applicant can choose to submit the report as more than one document. In this case the text portion of the report should be one document and the appendices can be one or more documents.

Module 5
The applicants should ordinarily provide the study reports as multiple documents (a core study report and appropriate appendices). Appendices should be organized in accordance with the ICH E3 guideline, which describes the content and format of the clinical study report.

Literature References in Modules 3, 4 and 5
Copies of literature references should ordinarily be submitted as individual documents (i.e., one for each reference). Literature References should be listed in the tables of contents.

Document Pagination and Segregation
Every document should be numbered starting at page one, except for individual literature references, where the existing journal page numbering is considered sufficient. It is not considered necessary to display the number as '1 of n' where n is the total number of pages in the document.

Additionally, all pages of a document should include a unique header or footer that briefly identifies its subject matter. In a paper-based drug submission, this same identifier should be used on a tab that precedes the document, to facilitate finding that document within the dossier.
If a section contains more than one document, a specific Table of Contents for that section can be included to identify the chronology and titles of the documents contained therein, e.g.

- Tab with “3.2.S.4.2 Analytical Procedures”
  - Table of Contents, listing the title of Procedure A, Procedure B, Procedure C
- Tab with “3.2.S.4.2 “Procedure A”;
  - Procedure A (i.e. document, page 1-n)
- Tab with “3.2.S.4.2 “Procedure B”;
  - Procedure B (i.e. document, page 1-n)
- Tab with “3.2.S.4.2 “Procedure C”;
  - Procedure C (i.e. document, page 1-n)

If a section contains only a single document (e.g. 3.2.S.1.1 Nomenclature), only a tab identified by “3.2.S.1.1 Nomenclature” should precede the document.

**Section Numbering within Documents**

In order to avoid 5th, 6th etc. level subheading numbering (e.g. 2.6.6.3.2.1) within a document, the applicant can use a shortened numbering string. In this case, the document number and the name (e.g. 2.6.6 Toxicology Written Summary) should appear in page headers or footers and then section numbering within the document can be used, for example, 1, 1.1, 2, 3, 3.1, 3.2 etc. Use of the full numbering string (e.g. 2.6.6.3.2.1) is also considered acceptable.

**Table of Contents Formatting**

**Module 2**

The 2.1 CTD Table of Contents should go down to the third (e.g. 2.3.S) or fourth (e.g. 2.3.S.1) level, depending on how a document is defined for the Quality Overall Summary. (See Definition of a document for Module 2.)

**Module 3**

The Table of Contents provided under 3.1 should cover the high-level section numbering, the associated section heading, and Volume number, in the order that they appear in the drug submission. This Table of Contents would be used to identify the contents of Module 3 as defined in the M4Q guideline. It should go down to the fifth level only (e.g. 3.2.P.2.1). Note that additional subsections and subheadings are defined in the M4Q guideline beyond this level (e.g. under 3.2.P.2) and this formatting should be used within the dossier, despite neither being stated in the 3.1 Table of Contents. The lower level Table of Contents described under Document Pagination and Segregation should be excluded from the 3.1 Table of Contents.

At the applicant’s discretion, a Table of Contents can also be included for a particular section that contains multiple documents, in order to identify the chronology and the document subject matter. If there is a desire to introduce additional headers or subsection numbering beyond those which are defined in the M4Q guideline, these should only be included within a document and should neither be created as a separate document or as a new subsection. In this case, a specific Table of Contents for that document can be included to identify the chronology and titles of the subsections contained therein. These documents and subsections should not appear in the 3.1 Table of Contents.
Furthermore, additional attachments or appendices should not be incorporated into this formatting, except as a document under a section where multiple documents might be provided. In this case, a cross-reference should be made within the relevant section to the attached or appended document. If there is a desire to append or attach additional information to a section that is comprised of only one document, this information should be incorporated within that document.

All Table of Contents title entries should either correspond to heading names and section numbering as defined in the M4Q guideline or to identifiers appearing on tabs (for a paper-based drug submission only), preferably by their full title, which should easily identify any abbreviated title that might be used on the corresponding tab. The Table of Contents should not specify any page numbers.

Literature References should be listed in a Table of Contents specific for this section.

Module 4
The Table of Contents for Module 4 should include all of the numerical items listed in the CTD guideline in order to identify all of the important components of the application (for example, 4.2.3.5.1 Fertility and early embryonic development) and should continue down to at least the level of the study report. Thus each study report should be identified in the table of contents. The sections of a study report could be identified in the Module 4 Table of Contents of the dossier or only in the Table of Contents of the individual study report.

Illustration of part of the Module 4 Table of Contents

4.2.3.2 Repeat-Dose Toxicity
- 4.2.3.2.1 Study aa-aaa: 30 day repeat dose toxicity study with Drug C in rat
- 4.2.3.2.2 Study bb-bbb: 6 month repeat dose toxicity study with Drug C in rat
- 4.2.3.2.3 Study cc-ccc: 30 day repeat dose toxicity study with Drug C in dog
- 4.2.3.2.4 Study dd-ddd: 6 month repeat dose toxicity study with Drug C in dog

4.2.3.3 Genotoxicity
- 4.2.3.3.1 In vitro
- 4.2.3.3.1 Study ee-eee: Ames test with Drug C

etc.

Module 5
The Table of Contents for Module 5 should include all of the numerical items listed in the CTD guideline in order to identify all of the important components of the application (for example, 5.3.5.1.1 Placebo Controlled Trials) and should continue down to at least the level of the clinical study report. Thus each clinical study report should be identified in the table of contents. The sections of a clinical study report (E3) could be identified in the Module 5 Table of Contents of the dossier or only in the Table of Contents of the individual clinical study report.
Illustration of part of the Module 5 Table of Contents

5.3.5 Reports of Efficacy and Safety Studies – Indication Z

5.3.5.1 Study Reports of Controlled Clinical Trials Pertinent to the Claimed Indication

5.3.5.1.1 Placebo Controlled Trials
5.3.5.1.1.1 Study xx-xxx: A double blind, placebo-controlled trial of Drug A in Indication Z
5.3.5.1.1.2 Study yy-yyyy: A double blind......

5.3.5.1.2 Active Controlled Trials
5.3.5.1.2.1 Study zz-zzz: A double blind, active controlled trial of Drug A vs. Drug C in Indication Z

5.3.5 Reports of Efficacy and Safety Studies – Indication Q

5.3.5.1 Study Reports of Controlled Clinical Trials Pertinent to the Claimed Indication etc.